Here's the Biggest Risk With Buying Ocugen Stock Right Now

Ocugen (NASDAQ: OCGN) practically came out of nowhere to become a huge winner. Its shares are up more than 500% year to date. The biotech quickly vaulted into the top 100 most popular stocks among Robinhood investors. 

All of this enthusiasm is based on Ocugen's deal with Bharat Biotech to market COVID-19 vaccine Covaxin in the U.S. Make no mistake about it: Bharat's vaccine is the real deal. It's already authorized for use in India. Last week, Bharat reported results from the second interim analysis of a phase 3 study of Covaxin that showed the vaccine achieved an overall efficacy of 78% and a 100% efficacy against severe COVID-19. 

But while the exuberance about Covaxin continues, Ocugen still faces several key hurdles. Here's the biggest risk with buying Ocugen stock right now.

Continue reading

Source Fool.com